Efficacy and Safety of Valproic Acid in Myelodysplastic Syndrome and Acute Myeloid Leukemia; a Narrative Review
Drug Res (Stuttg) DOI: 10.1055/a-2088-3718Loads of new therapeutic regimes have been turned up to manage Myelodysplastic
syndrome (MDS) and acute myeloid leukemia (AML), particularly in elderly
patients who are unfit for intensive chemotherapy. Despite accumulating
research, the best MDS and AML management approach is indeterminate.
Myelodysplastic syndrome implies a group of various hematopoietic stem cell
disorders that may progress to acute myeloid leukemia. These disorders are more
frequent in older adults. To the high rate of morbidity and abundant toxicities
related to the therapeutic approaches, also, the treatment would be challenging.
The clinical effectiveness of valproic acid, a histone deacetylase inhibitor, in
MDS and AML patients is unknown, even though it has demonstrated positive
activities to promote differentiation and apoptosis in cancer cells. We
investigated the clinical research on the effects of valproic acid in
conjunction with various drugs, including low-dose cytarabine, all-trans
retinoic acid, DNA-hypomethylating agents, hydrazine, and theophylline. We
conclude that VPA is a safe and effective treatment option for MDS and AML
patients, particularly when used in conjunction with all-trans retinoic acid,
DNA-hypomethylating drugs, and hydralazine. However, more randomized clinical
st...
Source: Drug Research - Category: Drugs & Pharmacology Authors: Omidkhoda, Navid Mahdiani, Sina Samadi, Sara Rahimi, Hossein Mohammadpour, Amir Hooshang Tags: Review Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Hydralazine | Leukemia | Myelodysplastic Syndrome | Stem Cell Therapy | Stem Cells | Study | Toxicology